Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 2. Thalidomide Efficacy—Studies of Thalidomide Alone in Newly Diagnosed and/or Previously Untreated Multiple Myeloma

Study ID

Thalidomide Dose Daily
[Median length of followup]

No. of Patients, Age, Sex, additional MM characteristics


Paraprotein Response


Phase II

Rajkumar, 200141

Quality 4/5

200-800 mg
[12 mo]

60 yr (38-75)
81% IgG
13% IgA
6% light chain only

Previously untreated, asymptomatic SMM or IMM


Overall response (≥25%)=81%

m protein reduction:
   (95% CI, 18-63%)   

[median duration of response not reached @ median 1 yr f/u]

Rajkumar, 200342

Quality 3/5

50-800 mg
[median f/u=NS]

61  (40-74)
55% M

Previously untreated, asymptomatic SMM (66%) or IMM (34%)

Reason for dx as "Indolent MM":
   Lytic lesions (n=7)
   Hgb < 11 g/dL (n=6)
   IgG 83%
   IgA 10%


Overall response (≥25%)=66%

m protein reduction:
   (95% CI, 18-54%)
   (95% CI, 46-82%)

Median time to PR=5 mo ( 2-9)

Median time to progression & median duration of response not reached.

PFS 80% @ 1 yr; 63% @ 2 yr

KM estimated OS @ 2 yr=96%

Abbreviations:  CI=confidence intervals, dL=deciliter, dx=diagnosis, f/u=followup, hgb=hemoglobin, IMM=indolent multiple myeloma,  KM=Kaplan-Meier, OS=overall survival, PFS=progression free survival,  PR=partial response, SMM=smoldering multiple myeloma

Return to Document
Proceed to Next Table

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care